Condition: Breast Neoplasm · Breast Cancer · Hormone Receptor Positive Tumor · Sponsor: Fudan University
The purpose of this study is to establish a prospective, multi-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.
This description comes directly from the study's public registry record.
Zhimin Shao, M.D · +86-021-64175590 · zhimingshao@yahoo.com
Always discuss trial participation with your own doctor first.
| Breast cancer institute of Fudan University Cancer Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05594095